SUPERIOR BACTERIAL VACCINES

based on a novel vaccine technology platform

targeting antimicrobial resistant bacterial infections

"Our core mission is to contribute to global health by providing new innovative vaccines overcoming the urgent medical problem of antimicrobial resistance. Utilizing our proprietary technology platform, we enable production of safe and superior immunogenic toxoid antigens for highly needed vaccines to disarm specific pathogenic bacteria without the need for non-specific antimicrobial treatment."

Proxi Biotech, 2023

ANTIMICROBIAL RESISTANCE (AMR)

One of the world's most pressing medical problems

1.27M

Die each year from AMR, and the number is increasing by the day

10M

Deaths from AMR each year by 2050, which is a bigger killer than cancer

€100 Trillion

Financial burden from AMR, reducing global economic output by up to 3.5%

Antibiotics are standard of care for bacterial infections, but their overuse and misuse is the root-cause for AMR!

WHAT WE DO

Proxi Biotech is an innovative biopharmaceutical company with a focus on utilizing its proprietary and patent-pending BACTOVAC technology platform for the development of novel, safe and highly immunogenic and efficacious vaccines against unmet need AMR infections.

Our BACTOVAC platform overcomes main barriers of traditional vaccine developing technologies, and fast-tracks the development of new and highly needed vaccines in widely untapped markets for the benefit of people and society.

About our technology

Vaccines are the best weapon against AMR

Production of lethal toxins is crucial for pathogenesis of many AMR bacterial infections

Most of these toxin-mediated infections can be prevented with effective toxoid vaccines

Toxoid vaccines will reduce AMR and the extensive use of antibiotics

Vaccines designed to only target secreted toxins avoid selecting for AMR

But current technologies for toxoid vaccine production are suboptimal

VACCINE PROGRAMS

TARGETING HIGH-PRIORITY UNMET NEEDS

All vaccines are developed by leveraging from the strength and versatility of our BACTOVAC platform

CDIFFVAC: A superior and broad-protective toxoid vaccine for treatment of recurrent Clostridium difficile infection

UTIVAC: A multi-faceted nasal vaccine for prevention and treatment of urinary tract infection caused by UPEC

PTVAC: A more immunogenic and longer-lasting toxoid nasal vaccine for prevention of whooping cough

About our vaccine programs

FOLLOW OUR PROJECTS

rj@proxibiotech.com